 |
Peregrine Pharmaceuticals Presents Promising Antiviral Data at 2009 Chemical and Biological Defense Science & Technology Conference
Nov 18, 2009
|
12.5 KB |
|
| |
TUSTIN, Calif., Nov 18, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that researchers presented positive data on progress in its federally funded preclinical viral hemorrhagic fever (VHF) program, confirming that its phosphatidylserine (PS)-targeting antibodies bind to VHF vir...
|
|
New Study in Clinical Cancer Research Shows Therapeutic Promise of Peregrine's Bavituximab With Radiation in a Lethal Brain Cancer Model
Nov 10, 2009
|
11.5 KB |
|
| |
TUSTIN, Calif., Nov 10, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHMD) today announced that a newly published study shows that a phosphatidylserine (PS)-targeting antibody similar to the company's lead product candidate bavituximab demonstrated potent anti-tumor activity when combined with rad...
|
|
Peregrine Pharmaceuticals Awarded Second Broad U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
Nov 4, 2009
|
12.8 KB |
|
| |
...
|
|
Peregrine Pharmaceuticals Regains Full Compliance With Nasdaq Continued Listing Requirements
Nov 3, 2009
|
9.3 KB |
|
| |
...
|
|
Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
Oct 21, 2009
|
10.9 KB |
|
| |
TUSTIN, Calif., Oct 21, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHMD) today reported positive results from its Phase II trial evaluating bavituximab in combination with docetaxel in patients with advanced breast cancer. Preliminary data at the end of the six planned treatment cycles in the Ph...
|
|
Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory Affairs
Oct 19, 2009
|
10.3 KB |
|
| |
TUSTIN, Calif., Oct 19, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHMD) today announced that Dr. Robert Garnick has joined the company as the head of regulatory affairs. Dr. Garnick was formerly the senior vice president of regulatory, quality and compliance at Genentech. During his 24-year c...
|
|
Peregrine Pharmaceuticals 1:5 Reverse Stock Split Takes Effect
Oct 19, 2009
|
9.5 KB |
|
| |
TUSTIN, Calif., Oct 19, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that the previously announced 1-for-5 reverse stock split of the Company's common stock will become effective at 9:30 a.m. EDT today. Peregrine's shares will continue to trade on the NASDAQ Capital Market un...
|
|
Peregrine Pharmaceuticals Announces Implementation of 1:5 Reverse Stock Split to Take Effect October 19, 2009
Oct 16, 2009
|
10.4 KB |
|
| |
TUSTIN, Calif., Oct 16, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that a previously approved reverse split of its common stock will take effect at the start of NASDAQ trading on Monday, October 19, 2009 on a 1-for-5 split-adjusted basis. Peregrine's shares will continue to...
|
|
Peregrine Pharmaceuticals Forms Anti-Viral Research Group to Oversee Its Anti-PS Infectious Disease Collaborations
Oct 7, 2009
|
14.4 KB |
|
| |
TUSTIN, Calif., Oct 07, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it has established a new Anti-Viral Research Group in its R&D organization. The new group has responsibility for coordinating, expanding and leveraging the company's multiple external collaborations alr...
|
|
Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
Oct 5, 2009
|
10.9 KB |
|
| |
TUSTIN, Calif., Oct 05, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported additional positive results in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC). Data previously reported from the i...
|
|
Avid Bioservices Becomes U.S. West Coast Partner of Boehringer Ingelheim's Global Production Alliance Network for Biologic Contract Manufacturing Services
Sep 21, 2009
|
11.5 KB |
|
| |
TUSTIN, Calif., Sept 21, 2009 /PRNewswire via COMTEX News Network/ -- Avid Bioservices, Inc., a leading provider of cGMP contract manufacturing of biologics and other key services, and Boehringer Ingelheim, a global leader in biopharmaceutical development and manufacturing, today announced that the two companies have entered into a global strategic...
|
|
Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program
Sep 8, 2009
|
11.0 KB |
|
| |
TUSTIN, Calif., Sept 08, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported completion of patient enrollment in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in advanced breast cancer patients. The trial's planned total of 46 patients has b...
|
|
Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2010
Sep 3, 2009
|
23.0 KB |
|
| |
TUSTIN, Calif., Sept 03, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced financial results for the first quarter of fiscal year (FY) 2010 ended July 31, 2009. Total revenues for the first quarter of FY 2010 increased 345% to $6,750,000, compared to $1,517,000 for the comparable ...
|
|
Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrine's Cotara(R) for Treatment of Brain Cancer
Sep 2, 2009
|
11.6 KB |
|
| |
BOSTON, Mass. and TUSTIN, Calif., Sept 02, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported that clinical investigators are presenting interim Phase II data showing that its brain cancer agent Cotara(R) appeared well tolerated and demonstrated encouraging signs of efficacy in patie...
|
|
Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
Sep 1, 2009
|
7.1 KB |
|
| |
TUSTIN, Calif., Sept 01, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that senior management will present at the Rodman & Renshaw 11th Annual Healthcare Conference on Thursday, September 10, 2009 at 10:25 am EDT. The conference will be held at the New York Palace Hotel in New...
|
|
Peregrine Pharmaceuticals Adds Noted Oncologist Dr. Bruce Chabner as Clinical Advisor to Support Advancement of Its Clinical Programs
Aug 31, 2009
|
9.4 KB |
|
| |
TUSTIN, Calif., Aug 31, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), today announced that noted cancer researcher Bruce Chabner, M.D., will serve as a clinical advisor to the company on the design of clinical trials for the bavituximab cancer program. Dr. Chabner is currently the clinical d...
|
|
Avid Bioservices Expands Executive Team As It Prepares For Continued Growth
Aug 28, 2009
|
11.5 KB |
|
| |
TUSTIN, Calif., August 28, 2009 – Avid Bioservices, Inc., a leading provider of cGMP contract manufacturing of biologics and other key services, today announced that it has further strengthened its executive team with the appointments of Truc Le as chief operating officer and Christopher Eso as vice president of business ...
|
|
Peregrine Pharmaceuticals to Report First Quarter FY 2010 Financial Results
Aug 27, 2009
|
7.2 KB |
|
| |
TUSTIN, Calif., Aug 27, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it will release its financial results for the first quarter of fiscal year 2010 on September 3, 2009 at 7:00 a.m. EDT and will host a conference call and webcast to discuss the results at 11:30 a.m. EDT ...
|
|
NIAID Awards New Grant to Expand Studies of Peregrine's Anti-PS Antibodies to Treat Viral Hemorrhagic Fevers
Aug 26, 2009
|
12.1 KB |
|
| |
TUSTIN, Calif., Aug 26, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID) has awarded a two-year, $763,000 grant to Philip Thorpe, Ph.D., of the University of Texas Southwestern Medical Center for research ...
|
|
Peregrine Pharmaceuticals to Present at the Jesup & Lamont 2009 Growth Stock & National Sales Conference
Jul 23, 2009
|
6.6 KB |
|
| |
TUSTIN, Calif., July 23, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that senior management will present at the Jesup & Lamont 2009 Growth Stock & National Sales Conference on Thursday, July 30, 2009 at 8:30 am EDT at the Boca Raton Resort & Club in Florida.
More information...
|
|
|
